Register now for the Tau Global Conference, April 24 and 25, in London and online

Registration is open for the 2025 Tau Global Conference, which brings together three major tau-focused conferences (Global Tau, EuroTau, and CurePSP Neuro) and is hosted by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation. Taking place April 24 and 25 in London, UK, and online, the Tau Global Conference plays a critical role in bringing together interdisciplinary researchers and perspectives to move tau research forward.

The hybrid conference provides a forum for members of academia, industry, philanthropy, and government to explore tau-related biology, biomarkers, therapeutics, and phenotypes; enhance interdisciplinary collaboration and alignment to address challenges in tau research; and foster talent development and secure funding for the study of tauopathies, with a focus on early-career researchers.

The program aims to provide a deeper understanding of research advancements in tauopathies, including primary tauopathies such as progressive supranuclear palsy, cortical basal degeneration, and frontotemporal dementia, as well as key issues impacting the tau research community.

Questions about the Tau Global Conference may be sent to [email protected].

In early December 2024, the bipartisan Building Our Largest Dementia (BOLD) Reauthorization Act was signed into law. The bill, which passed unanimously out of Congress, reauthorizes the BOLD Infrastructure for Alzheimer's Act (P.L.115-406) and will enable public health departments to implement effective dementia interventions.

“In the 5 years since the initial BOLD Act was signed into law, public health departments across the country have been making a real-world impact by successfully implementing effective Alzheimer's interventions, such as increasing early detection and diagnosis and reducing risk,” said Robert Egge, Alzheimer's Impact Movement (AIM) president and Alzheimer's Association chief public policy officer. “Today's reauthorization will build on this progress and expand the law's impact further into communities.”

The BOLD Reauthorization Act was championed by Sens. Susan Collins (R-Maine), Catherine Cortez Masto (D-Nev.), Shelley Moore Capito (R-W.Va.), and Tim Kaine (D-Va.) in the Senate, and Reps. Brett Guthrie (R-Ky.), Paul Tonko (D-N.Y.), Chris Smith (R-N.J.), and Maxine Waters (D-Calif.) in the House.

“We are grateful to the bill's sponsors for their tremendous bipartisan leadership in introducing the bipartisan BOLD Reauthorization Act and their steadfast commitment to the Alzheimer's and dementia community,” continued Egge.

The BOLD Act has been essential to creating and growing a public health infrastructure for dementia across the country. Through the law, the Centers for Disease Control and Prevention (CDC) has provided funding to state, local, and tribal public health departments to help them improve brain health in their communities. Since 2018, the CDC has made 66 awards to 45 states and local and tribal public health departments to help them implement effective dementia interventions such as reducing risk, increasing early detection and diagnosis, and supporting the needs of caregivers.

The BOLD Reauthorization Act was the third Alzheimer's Association/AIM priority legislation to pass unanimously and be signed into law in the 118th Congress. In October 2024, the NAPA Reauthorization Act (P.L. 118-92) and the Alzheimer's Accountability and Investment Act (P.L. 118-93) were signed into law.